Zentalis Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
Clinical-stage biopharmaceutical company developing small-molecule cancer therapies. This unaudited filing covers the quarter and nine months ended September 30, 2022. Zentalis had no approved products and generated no product-sales revenue. Its principal clinical programs were ZN-c3 (Wee1 inhibitor) and ZN-d5 (BCL-2 inhibitor); it also reported starting IND-enabling studies for a BCL-xL degrader.
Financial and liquidity highlights
| Metric | Q3 2022 | Nine months 2022 | Comparable 2021 |
|---|---|---|---|
| Research and development expense | $42.2 million | $132.1 million | $54.0 million and $137.2 million |
| General and administrative expense | $12.0 million | $43.4 million | $8.9 million and $31.2 million |
| Net loss attributable to Zentalis | $54.4 million; $0.96 per share | $181.8 million; $3.56 per share | $4.2 million and $108.7 million |
| Net cash used in operating activities | Not separately stated | $126.4 million | $117.1 million |
At September 30, 2022, cash and cash equivalents were $42.6 million and available-for-sale marketable securities were $379.2 million, totaling $421.7 million. Current assets were $433.9 million; current liabilities were $54.1 million; total liabilities were $100.5 million. The company reported no indebtedness. Management believed available cash, cash equivalents and marketable securities would fund operating expenses and capital expenditures into the first quarter of 2025, while noting estimates could prove imprecise. No revenue or meaningful operating margin was reported.
For the nine months, investing activities used $102.3 million, primarily reflecting purchases of marketable securities and property and equipment; financing activities provided $211.3 million. Financing included net proceeds from a May follow-on offering and an April direct offering to Pfizer. Common shares outstanding rose to 57.0 million from 45.5 million at year-end 2021.
Material changes versus prior periods
- Q3 R&D expense fell $11.8 million year over year, mainly because the prior-year period included nonrecurring R&D impairment and licensing milestone costs; lower manufacturing and collaboration costs also contributed. Clinical-trial, personnel and consulting costs increased.
- Nine-month R&D expense declined $5.0 million, as lower prior-year one-time costs, CMC costs and collaboration expense offset increased clinical-trial and personnel costs.
- G&A expense increased $3.1 million in Q3 and $12.2 million for the nine-month period, driven largely by compensation and share-based compensation, facilities, consulting and legal costs.
- Net loss attributable to Zentalis increased substantially year over year in Q3 and for the nine-month period. The 2021 comparison included a $51.6 million gain on deconsolidation of Zentera; 2022 included equity-method investment losses of $2.4 million in Q3 and $9.5 million year to date.
- Unrealized losses on available-for-sale securities were $2.3 million at quarter-end; management stated these were not credit-related and it did not intend, nor expect to be required, to sell before recovery.
Outlook, management commentary, risks and unusual items
- ZN-c3’s Phase 2 uterine serous carcinoma trial had enrolled and dosed 43 patients by September 14, 2022. The company described tolerability as acceptable and the safety profile as similar to or improved from previously disclosed data. Dose optimization was expected to extend the study timeline; a dosing update was anticipated in the first half of 2023.
- ZN-c3 was also being studied in solid tumors and combination trials, including with niraparib and, under a Pfizer collaboration announced in October 2022, with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer. ZN-d5 trials included monotherapy studies in hematologic malignancies and amyloidosis; the company had announced plans for a ZN-d5/ZN-c3 AML combination trial.
- The filing says clinical development of ZN-c5 and ZN-e4 was being discontinued following completion of existing trials. The company held a 40.3% equity interest in Zentera, which had regional rights in select Asian markets; its recorded equity-method investment was $28.0 million.
- Key risks include clinical-trial safety, efficacy and enrollment uncertainty; regulatory approval risk; reliance on CROs and third-party manufacturers, including manufacturing in China; potential supply-chain and COVID-19 disruptions; competition; intellectual-property risks; and the need for substantial additional capital. The company cautioned that it may need further financing and that future equity financing could dilute shareholders.
- The company reported no material legal proceedings requiring a loss liability and no off-balance-sheet arrangements. Management concluded there was no substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the interim financial statements.
Important facts for investors to verify
- Whether actual cash use and clinical spending remain consistent with the stated runway into Q1 2025, and what assumptions underpin that estimate.
- Upcoming ZN-c3 dose-optimization decisions, revised uterine serous carcinoma trial timing, and the quality and completeness of clinical data as trials mature.
- ZN-d5 clinical progress and the timing and status of the planned combination trial; also confirm the scope and consequences of discontinuing ZN-c5 and ZN-e4.
- The magnitude and persistence of equity-method losses from Zentera, its development progress, and the economics of the regional sublicenses.
- Potential further share issuance, stock-based compensation and dilution, including availability under the ATM program and equity plans.